Fostering scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union
EMA
2007 2009
2011 First ESVAC
report
First two orphan
medicines 2001
2005
2006 First conditional
approval First public 2017
hearing
2019 2020
1995 EMA established 1996
2000 2004 SME regulation
2014 2016 2018
2010 2012 2015
Relocation to the Netherlands completed
First two CAR-T medicines New Veterinary Medicines Regulation
Launch of PRIME (PRIority Medicines) scheme
Proactive publication of clinical data
First stem-cell medicine
First paediatric-use
marketing authorisation Falsified Medicines Directive
First marketing
authorisation for an ATMP Minor-use-minor-species
limited-market policy
First two biosimilar
medicines Paediatric Medicines
Regulation
Review of EU
pharmaceutical legislation
Orphan Medicines Regulation
First centrally authorised human medicine
Launch of international harmonisation programme for pharmaceuticals First centrally authorised
veterinary medicine
Clinical Trials Directive
First centrally authorised generic medicine New pharmacovigilance legislation First gene-therapy medicine
First joint strategy of EMA and national medicines authorities Amsterdam is announced as EMA's new home Mutual recognition
agreement on inspections
EMA elected as ICMRA chair First vaccine against Ebola
Herbal Medicines Directive SME office established